请输入关键字
请输入关键字
订购
*国家
中国
美国
中国香港
中国澳门
中国台湾
阿尔巴尼亚
阿尔及利亚
阿根廷
阿拉伯联合酋长国
阿鲁巴
阿曼
阿塞拜疆
阿森松岛
埃及
埃塞俄比亚
爱尔兰
爱沙尼亚
安道尔
安哥拉
安圭拉
安提瓜和巴布达
奥地利
奥兰群岛
澳大利亚
巴巴多斯
巴布亚新几内亚
巴哈马
巴基斯坦
巴拉圭
巴勒斯坦领土
巴林
巴拿马
巴西
白俄罗斯
百慕大
保加利亚
北马里亚纳群岛
贝宁
比利时
冰岛
波多黎各
波兰
波斯尼亚和黑塞哥维那
玻利维亚
伯利兹
博茨瓦纳
不丹
布基纳法索
布隆迪
朝鲜
赤道几内亚
丹麦
德国
迪戈加西亚岛
东帝汶
多哥
多米尼加共和国
多米尼克
俄罗斯
厄瓜多尔
厄立特里亚
法国
法罗群岛
法属波利尼西亚
法属圭亚那
法属南部领地
梵蒂冈
菲律宾
斐济
芬兰
佛得角
福克兰群岛
冈比亚
刚果(布)
刚果(金)
哥伦比亚
哥斯达黎加
格恩西岛
格林纳达
格陵兰
格鲁吉亚
古巴
瓜德罗普
关岛
圭亚那
哈萨克斯坦
海地
韩国
荷兰
荷属加勒比区
荷属圣马丁
黑山
洪都拉斯
基里巴斯
吉布提
吉尔吉斯斯坦
几内亚
几内亚比绍
加拿大
加纳
加纳利群岛
加蓬
柬埔寨
捷克
津巴布韦
喀麦隆
卡塔尔
开曼群岛
科科斯(基林)群岛
科摩罗
科索沃
科特迪瓦
科威特
克罗地亚
肯尼亚
库克群岛
库拉索
拉脱维亚
莱索托
老挝
黎巴嫩
立陶宛
利比里亚
利比亚
联合国
列支敦士登
留尼汪
卢森堡
卢旺达
罗马尼亚
马达加斯加
马恩岛
马尔代夫
马耳他
马拉维
马来西亚
马里
马其顿
马绍尔群岛
马提尼克
马约特
毛里求斯
毛里塔尼亚
美国本土外小岛屿
美属萨摩亚
美属维尔京群岛
蒙古
蒙特塞拉特
孟加拉国
秘鲁
密克罗尼西亚
缅甸
摩尔多瓦
摩洛哥
摩纳哥
莫桑比克
墨西哥
纳米比亚
南非
南极洲
南乔治亚和南桑威奇群岛
南苏丹
瑙鲁
尼加拉瓜
尼泊尔
尼日尔
尼日利亚
纽埃
挪威
诺福克岛
帕劳
皮特凯恩群岛
葡萄牙
日本
瑞典
瑞士
萨尔瓦多
萨摩亚
塞尔维亚
塞拉利昂
塞内加尔
塞浦路斯
塞舌尔
沙特阿拉伯
圣巴泰勒米
圣诞岛
圣多美和普林西比
圣赫勒拿
圣基茨和尼维斯
圣卢西亚
圣马丁岛
圣马力诺
圣皮埃尔和密克隆群岛
圣文森特和格林纳丁斯
斯里兰卡
斯洛伐克
斯洛文尼亚
斯瓦尔巴和扬马延
斯威士兰
苏丹
苏里南
所罗门群岛
索马里
塔吉克斯坦
泰国
坦桑尼亚
汤加
特克斯和凯科斯群岛
特里斯坦-达库尼亚群岛
特立尼达和多巴哥
突尼斯
图瓦卢
土耳其
土库曼斯坦
托克劳
瓦利斯和富图纳
瓦努阿图
危地马拉
委内瑞拉
文莱
乌干达
乌克兰
乌拉圭
乌兹别克斯坦
希腊
西班牙
西撒哈拉
新加坡
新喀里多尼亚
新西兰
匈牙利
休达及梅利利亚
叙利亚
牙买加
亚美尼亚
也门
伊拉克
伊朗
以色列
意大利
印度
印度尼西亚
英国
英属维尔京群岛
英属印度洋领地
约旦
越南
赞比亚
泽西岛
乍得
直布罗陀
智利
中非共和国
*省份
*城市
*姓名
*电话
*单位
*职位
*邮箱
*请输入验证码
*验证码
B-hNKP46 mice(CB-17 SCID)
Strain Name
CB17/lcr-PrkdcscidNcr1tm1(NCR1)Bcgen/Bcgen 
Common Name  B-hNKP46 mice(CB-17 SCID)
Background CB-17 SCID Catalog number 112259
Aliases  CD335, LY94, NK-p46, NKP46
Protein expression analysis

from clipboard


Strain specific NKP46 expression analysis in wild-type and B-hNKP46 mice(CB-17 SCID) by flow cytometry. Splenocytes were collected from CB-17 SCID (+/+) and homozygous B-hNKP46 mice(CB-17 SCID) (H/H), and analyzed by flow cytometry with species-specific NKP46 antibody. Mouse NKP46 was detectable in wild-type mice. Human NKP46 was exclusively detectable in homozygous B-hNKP46 mice(CB-17 SCID).


Protein expression of NKP46 in spleen


from clipboard


Strain specific NKP46 expression analysis in wild-type and B-hNKP46 mice(CB-17 SCID) by flow cytometry. Splenocytes were collected from CB-17 SCID(+/+) and homozygous B-hNKP46 mice(CB-17 SCID)(H/H) (n=3, 6-week old), and analyzed by flow cytometry with species-specific NKP46 antibody. Mouse NKP46 was detectable in wild-type mice. Human NKP46 was exclusively detectable in homozygous B-hNKP46 mice(CB-17 SCID).

Protein expression of NKP46 in bone marrow

from clipboard


Strain specific NKP46 expression analysis in wild-type and B-hNKP46 mice(CB-17 SCID) by flow cytometry. Bone marrow were collected from CB-17 SCID(+/+) and homozygous B-hNKP46 mice(CB-17 SCID)(H/H) (n=3, 6-week old), and analyzed by flow cytometry with species-specific NKP46 antibody. Mouse NKP46 was detectable in wild-type mice. Human NKP46 was exclusively detectable in homozygous B-hNKP46 mice(CB-17 SCID).

Analysis of leukocytes cell subpopulation in spleen

from clipboard


Analysis of spleen leukocyte subpopulations by FACS. Splenocytes were isolated from female CB-17 SCID and B-hNKP46 mice(CB-17 SCID) (n=3, 6-week-old). Flow cytometry analysis of the splenocytes was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live cells were gated for the CD45+ population and used for further analysis as indicated here. B. Results of FACS analysis. Percent of T cells, B cells, NK cells, dendritic cells, granulocytes, monocytes and macrophages in homozygous B-hNKP46 mice(CB-17 SCID) were similar to those in the CB-17 SCID mice, demonstrating that NKP46 humanized does not change the overall development, differentiation or distribution of these cell types in spleen. Values are expressed as mean ± SD.

Analysis of leukocytes cell subpopulation in bone marrow

from clipboard


Analysis of spleen leukocyte subpopulations by FACS. Bone marrow cells were isolated from female CB-17 SCID and B-hNKP46 mice(CB-17 SCID) (n=3, 6-week-old). Flow cytometry analysis of the splenocytes was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live cells were gated for the CD45+ population and used for further analysis as indicated here. B. Results of FACS analysis. Percent of T cells, B cells, NK cells, dendritic cells, granulocytes, monocytes and macrophages in homozygous B-hNKP46 mice(CB-17 SCID) were similar to those in the CB-17 SCID mice, demonstrating that NKP46 humanized does not change the overall development, differentiation or distribution of these cell types in bone marrow. Values are expressed as mean ± SD.

Analysis of leukocytes cell subpopulation in blood

from clipboard


Analysis of spleen leukocyte subpopulations by FACS. Blood cells were isolated from female CB-17 SCID and B-hNKP46 mice(CB-17 SCID) (n=3, 6-week-old). Flow cytometry analysis of the splenocytes was performed to assess leukocyte subpopulations. A. Representative FACS plots. Single live cells were gated for the CD45+ population and used for further analysis as indicated here. B. Results of FACS analysis. Percent of T cells, B cells, NK cells, dendritic cells, granulocytes, monocytes and macrophages in homozygous B-hNKP46 mice(CB-17 SCID) were similar to those in the CB-17 SCID mice, demonstrating that NKP46 humanized does not change the overall development, differentiation or distribution of these cell types in blood. Values are expressed as mean ± SD.


Protein expression analysis via immunohistochemistry(IHC)


from clipboard


IHC of mouse ileum (upper panel) and spleen (bottom panel)

Image 2. Mouse ileum, huNKP46 IHC, approximately 200x. (2A) CB-17 SCID mouse. Labeling for huNKP46 is limited to nonspecific staining. The superficial epithelium of the mucosa (M) and smooth muscle of the tunica muscularis externa (TM) exhibit light nonspecific blushing. The submucosa (SM) is indicated. (2B) B-hNKP46 mice(CB-17 SCID). Small numbers of scattered round cells in the lamina propria (LP) exhibit moderate to strong membranous to cytoplasmic labeling (black arrows). There is light background nonspecific labeling similar to that in (2A). The mucosa (M), submucosa (SM), and tunica muscularis externa (TM) are indicated. 

Image 4. Mouse spleen, huNKP46 IHC, approximately 200x. (4A) CB-17 SCID mouse. There is light nonspecific background labeling of erythrocytes/ serum in the red pulp. Red pulp (RP) is indicated. (4B) BhNKP46 mice(CB-17 SCID). Moderate to large numbers of scattered round cells exhibit moderate to strong membranous to cytoplasmic labeling (black arrows). Red pulp (RP) is indicated.

Note: This experiment was performed by the client using CB-17 SCID and B-hNKP46 mice(CB-17 SCID). All the other materials were provided by the client.



In vivo efficacy of anti-human NKP46-based Ab in B-hNKP46 mice(CB-17 SCID)


from clipboard


Antitumor activity of anti-human NKP46-based Ab in B-hNKP46 mice(CB-17 SCID). (A) Anti-human NKP46-based Ab inhibited BxPC-3 tumor growth in B-hNKP46 mice(CB-17 SCID). BxPC-3 cells (5E6) were subcutaneously implanted into B-hNKP46 mice(CB-17 SCID) (male, 7-8 week-old, n=4). Mice were grouped when tumor volume reached approximately 150-200 mm3, at which time they were treated with anti-human NKP46-based Ab with doses and schedules indicated in panel A. (B) Body weight changes during treatment. As shown in panel A, anti-human NKP46-based Ab was efficacious in controlling tumor growth in B-hNKP46 mice(CB-17 SCID). Values are expressed as mean ± SEM. (All antibodies were provided by the clients)


In vivo efficacy of anti-human NKP46-based Ab-individual tumor growth curves 


from clipboard


Antitumor activity of anti-human NKP46-based Ab in B-hNKP46 mice(CB-17 SCID). (A) Anti-human NKP46-based Ab inhibited BxPC-3 tumor growth in B-hNKP46 mice(CB-17 SCID). BxPC-3 cells (provided by a client) (5E6) were subcutaneously implanted into B-hNKP46 mice(CB-17 SCID) (male, 7-8 week-old, n=4). Mice were grouped when tumor volume reached approximately 150-200 mm3, at which time they were treated with anti-human NKP46-based Ab with doses and schedules indicated in panel A. (B) Body weight changes during treatment. As shown in panel A, anti-human NKP46-based Ab was efficacious in controlling tumor growth in B-hNKP46 mice(CB-17 SCID). Values are expressed as mean ± SEM. Note:
Note: This experiment was performed by the client using B-hNKP46 mice(CB-17 SCID). All the other materials were provided by the client.



In vivo efficacy of anti-human NKP46-based Ab in B-hNKP46 mice(CB-17 SCID)




from clipboard


Antitumor activity of anti-human NKP46-based Ab in B-hNKP46 mice(CB-17 SCID). (A) Anti-human NKP46-based Ab inhibited BxPC-3 tumor growth in B-hNKP46 mice(CB-17 SCID). BxPC-3 cells (5E6) were subcutaneously implanted into B-hNKP46 mice(CB-17 SCID) (male, 7-8 week-old, n=6). Mice were grouped when tumor volume reached approximately 100-150 mm3, at which time they were treated with anti-human NKP46-based Ab with doses and schedules indicated in panel A. (B) Body weight changes during treatment. As shown in panel A, anti-human NKP46-based Ab was efficacious in controlling tumor growth in B-hNKP46 mice(CB-17 SCID). Values are expressed as mean ± SEM. (All antibodies were provided by the clients)


In vivo efficacy of anti-human NKP46-based Ab-individual tumor growth curves 


from clipboard


Antitumor activity of anti-human NKP46-based Ab in B-hNKP46 mice(CB-17 SCID). (A) Anti-human NKP46-based Ab inhibited BxPC-3 tumor growth in B-hNKP46 mice(CB-17 SCID). BxPC-3 cells (provided by a client) (5E6) were subcutaneously implanted into B-hNKP46 mice(CB-17 SCID) (male, 7-8 week-old, n=4). Mice were grouped when tumor volume reached approximately 150-200 mm3, at which time they were treated with anti-human NKP46-based Ab with doses and schedules indicated in panel A. (B) Body weight changes during treatment. As shown in panel A, anti-human NKP46-based Ab was efficacious in controlling tumor growth in B-hNKP46 mice(CB-17 SCID). Values are expressed as mean ± SEM. Note:
Note: This experiment was performed by the client using B-hNKP46 mice(CB-17 SCID). All the other materials were provided by the client.

In vivo efficacy of anti-human NKP46 antibodies

from clipboard


Antitumor activity of anti-human NKP46 antibodies (provided by a client) in B-hNKP46 mice(CB-17 SCID). (A) Anti-human NKP46 antibodies inhibited NCI-N87 tumor growth in B-hNKP46 mice(CB-17 SCID). NCI-N87 cells (provided by a client) were subcutaneously implanted into homozygous B-hNKP46 mice(CB-17 SCID)(female, 7-week-old, n=7). Mice were grouped when tumor volume reached approximately 200-250 mm3, at which time they were intraperitoneally injected with anti-human NKP46 antibodies indicated in panel. (B) Body weight changes during treatment. As shown in panel A, anti-human NKP46 antibodies were efficacious in controlling tumor growth in B-hNKP46 mice(CB-17 SCID), demonstrating that the B-hNKP46 mice(CB-17 SCID) provide a powerful preclinical model for in vivo evaluation of anti-human NKP46 antibodies. Values are expressed as mean ± SEM. Significance was determined by two-way ANOVA test.  *P < 0.05, **P < 0.01, ***P < 0.001. The overage of this tumor model is 43%.
Note: This experiment was performed by the client using B-hNKP46 mice(CB-17 SCID). All the other materials were provided by the client.

In vivo efficacy of anti-human NKP46-based Ab-individual tumor growth curves 

from clipboard



Antitumor activity of anti-human NKP46 antibodies (provided by a client) in B-hNKP46 mice(CB-17 SCID). (A) Anti-human NKP46 antibodies inhibited NCI-N87 tumor growth in B-hNKP46 mice(CB-17 SCID). NCI-N87 cells (provided by a client) were subcutaneously implanted into homozygous B-hNKP46 mice(CB-17 SCID)(female, 7-week-old, n=7). Mice were grouped when tumor volume reached approximately 200-250 mm3, at which time they were intraperitoneally injected with anti-human NKP46 antibodies indicated in panel. (B) Body weight changes during treatment. As shown in panel A, anti-human NKP46 antibodies were efficacious in controlling tumor growth in B-hNKP46 mice(CB-17 SCID), demonstrating that the B-hNKP46 mice(CB-17 SCID) provide a powerful preclinical model for in vivo evaluation of anti-human NKP46 antibodies. Values are expressed as mean ± SEM. Significance was determined by two-way ANOVA test.  *P < 0.05, **P < 0.01, ***P < 0.001. The overage of this tumor model is 43%.
Note: This experiment was performed by the client using B-hNKP46 mice(CB-17 SCID). All the other materials were provided by the client.